dm+d
18757911000001104
Medicine Compliance Aid Stability
IlaxtenMenarini Pharmaceuticals International SRL
Menarini Pharmaceuticals International SRL
Ilaxten
Tablet 20mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
Does not require any special storage conditions
1 November 2022
Lactation Safety Information
Cetirizine/Loratadine
Non-sedating antihistamine
No published evidence of safety
22 May 2017
New Medicines
IlaxtenAllergic rhinoconjunctivitis and urticaria in children
Information
Ilaxten
New formulation
Menarini
Not Known
Development and Regulatory status
Launched
None
None
October 2020
Nov 20Oral solution formulation is now also available in the UK [6].
Nov 20A 2.5mg/ml oral solution was also approved by the MHRA in Feb 19. This costs £5 per 120ml bottle [4,5].
Oct 20Ilaxten 10mg orodispersible tablets are available is the UK, costing £5 per 30 tablets (POM) [3].
Feb 19New 10mg orodispersible formulation approved by the MHRA, indicated for symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. Ilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20kg [2].
Category
A non-sedating, long-acting histamine antagonist with selective peripheral H1 receptor antagonist affinity and no affinity for muscarinic receptors. A 10mg orodispersible formulation and oral solution.
Allergic rhinitis is a common problem, affecting over 20% of the UK population. School-aged children and adolescents are more likely to have seasonal allergic rhinitis, whereas adults tend to have persistent allergic rhinitis. Peak onset is in children and adolescents. Allergic rhinitis is a common condition in children and becoming more prevalent. In the UK, 10% of 6- to 7-year-olds have the condition, and 15-19% of 13- to 14-year-olds [1].
Allergic rhinoconjunctivitis and urticaria in children
Oral
Allergic conjunctivitis - ophthalmic formulation
Information
New formulation
Faes Farma
Faes Farma
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Category
Selective histamine H1 antagonist
In general practice, allergic conjunctivitis accounts for four to five consultations per 1,000 patients each year. About 15% of these are allergic, and about half of allergic cases are seasonal. Allergies affect about 20% of the population, of whom about 20% experience eye problems [1].
Allergic conjunctivitis - ophthalmic formulation
Topical